Novartis gene therapy Itvisma approved in EU for spinal muscular atrophy
Seeking Alpha ·
Novartis ( NVS ) on Thursday announced that the European Commission approved its gene therapy. Itvisma (onasemnogene abeparvovec) for children aged two years and older with spinal muscular atrophy, a rare neuromuscular disorder. Accordingly, the one-time therapy will be available across all 27
DYAX Investor Sentiment
Bullish (Long) 57% · Bearish (Short) 43%
380 participants
Related News
- Insulet Omnipod recall listed as Class I by FDA
- Palantir upgraded to Buy, Rivian lifts delivery outlook, Robinhood's new product
- Genuine Parts gains on report it received bid from O'Reilly for auto-parts arm
- Sector Update: Tech Stocks Fall Late Afternoon
- Chevron upgraded at Wolfe on strong cash flow outlook
- Anthropic AI Ban Reversal Raises Fresh Investor Questions